NT

Abliva ABFRA Abliva Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.028

Micro

Exchange

XFRA - Deutsche Boerse AG

NTP.F Stock Analysis

NT

Uncovered

Abliva AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-2/100

Low score

Market cap $B

0.028

Dividend yield

Shares outstanding

1 056.3 B

Abliva AB operates as a biopharmaceutical company, which engages in the research and development of medicines for the treatment of primary mitochondrial diseases. The company is headquartered in Lund, Skane. The company went IPO on 2008-10-03. The firm focuses on the development of novel treatments for primary mitochondrial diseases.

View Section: Eyestock Rating